Cannabis use is associated with measurable increases in the risk of psychosis, depression, and other psychiatric problems, with heavier and earlier use generally carrying greater risk. But the relationship between weed and mental health is not a simple cause-and-effect story. Genetic vulnerability, product potency, age of first use, and the specific cannabinoid profile all shape what happens to any individual brain. The science has matured considerably in the past two decades, and the findings are more nuanced than either “weed is harmless” or “weed will make you crazy.”
Psychosis and High-Potency Cannabis
The strongest and most consistent evidence linking cannabis to psychiatric harm involves psychosis. In a London case-control study, people experiencing a first episode of psychosis were far more likely to have used high-potency cannabis (the kind sometimes called “skunk”) than healthy controls. Among cannabis users in the psychosis group, roughly four in five had used high-potency products, compared with about a third of the control group.1PubMed Central. High-potency cannabis and the risk of psychosis A follow-up study from the same research group found that daily users of high-potency cannabis were more than five times as likely to be diagnosed with a psychotic disorder compared with people who never used.2The Lancet Psychiatry. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study
What makes high-potency products riskier appears to come down to the balance of cannabinoids they contain. THC, the primary psychoactive compound, can induce transient psychotic symptoms even in healthy people at sufficient doses. Traditional hashish contains cannabidiol (CBD) alongside THC, and CBD appears to buffer some of THC’s psychosis-inducing effects. Modern high-potency strains and concentrates have been bred for maximum THC while CBD content has dropped to near zero.3PubMed Central. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis This shift in the commercial cannabis market matters: the weed available today is not the same product that was studied in the 1970s and 1980s.
Genetic Vulnerability and Who Is Most at Risk
Not everyone who uses cannabis develops psychotic symptoms, and genetics help explain why. A systematic review of genetic studies found that certain variations in genes involved in dopamine signaling are consistently linked to higher risk of cannabis-induced psychosis. The most replicated finding involves a gene called COMT: people carrying a particular variant (the Val allele) appear more susceptible.4PubMed. Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms Another gene, AKT1, has received attention because people with a specific genotype (C/C at one location) who used cannabis before developing a psychotic disorder showed worse cognitive performance than cannabis users with a different genotype, suggesting a biological pathway through which the gene-cannabis interaction increases risk.5PubMed Central. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder
The causal picture gets even more tangled. A large genetic study published in The Lancet Psychiatry found that psychotic disorders themselves have a causal effect on cannabis use, not just the other way around. In other words, the genetic liability that predisposes someone to schizophrenia or bipolar disorder also predisposes them to use cannabis. At the same time, lifetime cannabis use showed a causal effect on bipolar disorder specifically.6The Lancet Psychiatry. Genetic association between psychotic disorders and cannabis use phenotypes and their shared liabilities This bidirectional relationship helps explain why it has been so difficult to draw a clean arrow from cannabis to psychosis: the two share genetic roots, and they also influence each other.
Depression and Bipolar Disorder
A meta-analysis pooling longitudinal studies found that cannabis users had a modestly higher chance of developing depression than non-users. Heavy users faced a larger increase in risk.7PubMed. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies That said, at least one population-based study concluded that after adjusting for baseline differences like socioeconomic status and pre-existing mental health conditions, much of the apparent link between cannabis and a worse course of major depression faded. The researchers found that cannabis users had more specific depressive symptoms (anhedonia, sleep disruption, psychomotor problems) at follow-up, but rates of remission did not differ, and the associations with suicidality and quality of life were largely explained by other factors.8PubMed. Cannabis use and the course and outcome of major depressive disorder: A population based longitudinal study
For bipolar disorder, the picture is more worrying. A study tracking people after their first hospitalization for mania found that those with a co-occurring cannabis use disorder spent more time in manic and mixed episodes and experienced more rapid cycling between mood states.9JAMA Psychiatry. Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania A systematic review and meta-analysis confirmed that cannabis use may both trigger a first episode of bipolar disorder and worsen the illness in people who already have it.10PubMed Central. Cannabis use and its relationship with bipolar disorder: A systematic review and meta-analysis
Anxiety and the Dose Problem
Many people report using cannabis specifically to manage anxiety, and at low doses some do feel calmer. But experimental research paints a more complicated picture. When researchers pooled data from four placebo-controlled trials of vaporized and oral cannabis in healthy adults, anxiety-related ratings (feeling nervous, restless, heart racing) increased in a dose-dependent manner. Higher THC doses produced more anxiety, not less. Women in the trials reported greater increases in anxiety than men, an effect that persisted even after accounting for body weight and blood THC levels.11PubMed Central. THC, CBD, and Anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis’ primary cannabinoids The short version: low-dose THC might reduce anxiety for some people in the moment, while higher doses reliably increase it. That makes cannabis an unreliable anxiety treatment, because the therapeutic window is narrow and people tend to escalate their use over time.
Suicidality
An umbrella review covering multiple meta-analyses and systematic reviews found a consistent positive association between cannabis use and suicidal thoughts and attempts in the general population, military veterans, and people with depression or bipolar disorder. Heavy cannabis use showed the strongest link, with one pooled analysis finding that heavy users had roughly three times the odds of a suicide attempt compared with non-users.12PubMed Central. Suicidality risk after using cannabis and cannabinoids: An umbrella review A large U.S. study found that cannabis use disorder was associated with a higher prevalence of suicidal ideation, plans, and attempts in both men and women, but the association was significantly stronger in women. Among those with cannabis use disorder and a major depressive episode, women were about 50 percent more likely to have a suicide plan than men in the same situation.13JAMA Network Open. Associations of Suicidality Trends With Cannabis Use as a Function of Sex and Depression Status
What Happens to Thinking and Memory
Cannabis impairs cognitive function at multiple levels, from motor coordination to higher-order planning, decision-making, and emotional regulation. The severity of those deficits tracks with how much, how recently, how early, and how long someone has been using.14PubMed Central. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions A study comparing long-term heavy users to shorter-term users and non-users found that long-term users recalled fewer words on memory tests, showed impaired learning and retention, and performed worse on attention tasks. These deficits correlated with years of use and persisted after controlling for recent consumption and other drug use.15JAMA. Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment
Brain imaging adds another dimension. A 2024 study found that heavy lifetime cannabis use was associated with lower brain activation during a working memory task, particularly in regions involved in decision-making and self-regulation (the anterior insula, medial prefrontal cortex, and dorsolateral prefrontal cortex). Recent cannabis use also correlated with poorer performance, though that finding was less statistically robust.16JAMA Network Open. Brain Function Outcomes of Recent and Lifetime Cannabis Use The open question is how much of this recovers with sustained abstinence. Some evidence suggests partial recovery after weeks to months without use, but the degree of recovery in long-term heavy users remains unclear.
The Adolescent Brain
Adolescents are a uniquely vulnerable population. The brain’s endocannabinoid system plays a central role in shaping how reward and stress circuits develop during the teenage years, and introducing external cannabinoids into that process appears to carry outsized consequences. The primary psychiatric symptoms linked to adolescent cannabis use are an increased risk of addiction, depressive symptoms, and psychotic symptoms.17PubMed Central. Cannabis and the Developing Adolescent Brain This is not just a matter of “teens do risky things.” The biology of the developing brain makes it more sensitive to cannabis than an adult brain, and the effects of early use tend to compound over time.
Sleep and Withdrawal
Cannabis is one of the most commonly cited sleep aids among users, but a recent systematic review and meta-analysis found the evidence surprisingly thin. Early studies suggesting that THC reduces REM sleep were based on small trials using high doses with serious methodological limitations. More recent, larger studies using lower therapeutic doses have reported mixed results, with many showing no significant REM suppression at all.18PubMed. Cannabis and sleep architecture: A systematic review and meta-analysis What is clear, though, is the other side of the equation: withdrawal from regular cannabis use consistently disrupts sleep, causing longer time to fall asleep, shorter total sleep, and REM rebound. People who start using cannabis for sleep may end up in a cycle where they feel they cannot sleep without it, not because cannabis is particularly good for sleep but because quitting makes sleep temporarily worse.
Cannabis withdrawal more broadly is a real clinical phenomenon. People with cannabis use disorder are about six times more likely to also meet criteria for alcohol or nicotine use disorder, and roughly four times more likely to have a mood disorder and about three times more likely to have an anxiety disorder.19PubMed Central. Clinical management of cannabis withdrawal These overlapping conditions make it harder to study cannabis’s effects in isolation and harder for people to quit.
The Self-Medication Paradox
Surveys consistently show that people report using cannabis to manage pain, anxiety, depression, sleep problems, and PTSD. In one cross-sectional study spanning 18 countries, over half of participants who considered their use “medical” listed anxiety and depression among their top reasons.20PubMed Central. Cannabis and Mental Illness: A Review But a systematic review and meta-analysis of clinical trial evidence found that cannabinoids had no significant effect on primary outcomes for treating anxiety, PTSD, or most substance use disorders. The expansion of medical cannabis programs, the authors argued, has been driven more by the perception that cannabis is low-risk than by good evidence of effectiveness.21The Lancet Psychiatry. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis
One exception worth noting involves PTSD-related nightmares. THC and its pharmaceutical analogue nabilone have been found to reliably reduce the intensity and frequency of post-traumatic nightmares, though they do not cure PTSD itself.22Europe PMC. Nightmares and the Cannabinoids This is one of the few areas where the clinical evidence and the self-reported experience of users genuinely align.
CBD as a Separate Story
Cannabidiol (CBD) deserves its own discussion because its effects on mental health appear to be largely distinct from THC’s. A scoping review concluded that the most promising preliminary findings for CBD relate to psychotic symptoms and anxiety, though the authors stressed that there is not yet enough high-quality evidence to recommend CBD for any psychiatric disorder.23PubMed Central. A scoping review of the use of cannabidiol in psychiatric disorders A more detailed review counted positive data from 17 randomized controlled trials for anxiety, 8 for psychosis and schizophrenia, 4 for PTSD, and 3 for substance abuse.24PubMed Central. The therapeutic potential of purified cannabidiol That is a relatively large body of trial-level evidence, but “positive data” in individual trials does not mean the question is settled. Most of these trials are small, and the optimal doses, durations, and patient populations remain unclear. Still, CBD is the one cannabinoid where the direction of the evidence runs toward potential psychiatric benefit rather than harm.
Sex Differences in Cannabis Effects
A growing body of research suggests that women may be more sensitive to the effects of cannabis than men. Preclinical and early clinical data point to greater reactivity to cannabinoids in women, and women who develop problematic use tend to progress from first use to dependence faster than men, a pattern researchers call the “telescoping effect.”25PubMed Central. Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations As noted earlier, women also show greater dose-dependent increases in anxiety from THC and stronger associations between cannabis use disorder and suicidality. These sex differences are still being worked out, but they suggest that blanket statements about cannabis risk may understate the danger for women specifically.
Prenatal Cannabis Exposure
Cannabis use during pregnancy is rising, partly because some people believe it helps with morning sickness and partly because the normalization of cannabis use extends to pregnant populations. The research on offspring mental health is concerning. A large study using data from the Adolescent Brain Cognitive Development (ABCD) study found that children whose mothers continued using cannabis after learning they were pregnant had higher rates of psychotic-like experiences, externalizing problems, and attention and social difficulties compared with unexposed children or those exposed only before the mother knew she was pregnant.26JAMA Psychiatry. Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study Animal and human research suggests that one mechanism may involve changes to the immune environment of the placenta: cannabis exposure during pregnancy is associated with reduced pro-inflammatory cytokine levels, which has been linked to increased anxiety, aggression, and hyperactivity in offspring.27PubMed. Effects of prenatal cannabis exposure on offspring mental health: A focus on the role of the immune system
Terpenes, the Entourage Effect, and Why Strain Names Mean Less Than You Think
Walk into a dispensary and you will hear about indica versus sativa, strain-specific terpene profiles, and the “entourage effect,” the idea that the various compounds in the cannabis plant work together to produce different therapeutic or psychoactive outcomes. There is some biological basis for this: cannabis produces dozens of terpenes (the aromatic compounds responsible for its smell), and preclinical research suggests some of these may have independent effects on mood and stress. Myrcene is linked to relaxation, linalool to stress relief, and beta-caryophyllene to pain modulation.28PubMed Central. The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review The concept has generated serious scientific interest, and researchers have reviewed the possibility that adding specific terpenes to cannabinoids might enhance antidepressant or anxiolytic effects.29PubMed Central. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
But the honest state of the science is that the entourage effect remains unproven in humans. The terpene research is almost entirely preclinical, meaning it comes from cell cultures and animal models, not controlled human trials. And commercially available cannabis products are wildly inconsistent in their actual chemical profiles regardless of what the label says. A Mendelian randomization study using genetic data found that genetically predicted lifetime cannabis use was associated with increased risk of ADHD in women and of Parkinson’s disease, adding to the picture that cannabis exposure has real neuropsychiatric consequences that extend beyond psychosis and mood.30PubMed Central. Association Between Cannabis Use and Neuropsychiatric Disorders: A Two-sample Mendelian Randomization Study As the legal market expands and product potency continues to climb, the gap between what consumers believe about cannabis and what the evidence actually supports is widening rather than narrowing.